DaVita Inc.: The Economics of America's Dialysis Duopoly

I. Introduction & Episode Roadmap

Picture the least glamorous business you can imagine. It is a chain of clinical storefronts wedged into suburban strip malls, next to the nail salon and the vape shop. Inside, several hundred thousand very sick Americans recline in vinyl chairs three times a week, four hours at a stretch, while a machine pulls their blood out of their body, scrubs it clean of the toxins their failed kidneys can no longer filter, and pumps it back in. The core service is reimbursed by the federal government at a rate that, on many days, does not cover the cost of delivering it. The industry grows barely faster than the American population. It has been the target of whistleblower lawsuits, criminal indictments, and nearly a billion dollars in fraud settlements.

Now consider that this business became one of the great quiet compounders of Warren Buffett's Berkshire Hathaway, a stock the conglomerate has held since 2011 and grown into a stake capped by contract at 45% of the company.¹ How does a slow-growing, negative-margin, heavily regulated medical service turn into a machine that manufactures double-digit earnings-per-share growth year after year?

That is the puzzle of DaVita Inc. (NYSE: DVA), a company that in fiscal 2025 reported $13.643 billion in consolidated revenue and controls roughly 37% of the United States outpatient dialysis market.²³ Alongside its German-owned archrival Fresenius Medical Care, it forms one of the tightest duopolies in all of American healthcare — the two firms together operate nearly 80% of the nation's dialysis clinics.³ It is, in the truest sense, a clinical utility: demand is captive, competition is scarce, and the customers cannot leave without dying.

But the moat is under siege from two directions at once, and both are existential rather than incremental. The first is pharmaceutical. In October 2023, Novo Nordisk stopped a major clinical trial early because its GLP-1 drug semaglutide — the molecule inside Ozempic and Wegovy — was protecting kidneys so effectively that it became unethical to keep patients on placebo.⁴ If these drugs bend the curve of chronic kidney disease downward, they threaten the supply of new patients feeding into DaVita's clinics for decades to come. The second threat is judicial. In June 2022, the Supreme Court handed down a 7–2 ruling in Marietta Memorial Hospital v. DaVita that gave employers a legal roadmap to strip dialysis coverage out of their health plans — striking at the precise cross-subsidy that keeps the entire industry profitable.[^5]

This is the story of how those two pressures came to bear on a business that most investors have never thought about. We will start in 1972, with a single clause tucked into a Nixon-era spending bill that created the only disease-specific universal healthcare entitlement in American history. We will meet Kent Thiry, the sword-wielding former consultant who dressed as a Musketeer, called his company a "Village," and dragged it back from bankruptcy. We will dissect the brutal, brilliant arithmetic of the "payer mix," the mechanism by which roughly one in ten patients generates essentially all of the profit. We will walk through the whistleblower scandals and the federal settlements that management came to treat almost as a cost of doing business. We will examine the $4.4 billion diversification blunder, the Berkshire share-cannibalization playbook, and finally the modern battle Javier Rodriguez is fighting to move patients into their homes while defending the fortress against Ozempic and the courts.

Let us begin where the market itself begins: with a law.

Subscribe on LinkedIn

↑ Back to Top

II. The 1972 Miracle: Nixon and the Genesis of Universal Dialysis

Before 1972, kidney failure was, for almost everyone who suffered it, a death sentence with a date attached. The technology to save these patients existed — Dutch physician Willem Kolff had built the first working artificial kidney out of sausage casings and a rotating drum during the Second World War — but the machines were monstrously expensive and desperately scarce. There were not enough to go around, and so someone had to decide who lived.

In Seattle, at what became known as the Seattle Artificial Kidney Center, that decision was outsourced to a committee. A panel of ordinary citizens — a lawyer, a minister, a banker, a housewife, a labor leader, a surgeon — met in anonymity to review the case files of dying patients and choose which of them would receive one of the center's precious dialysis slots. The press, when it discovered them, called them the "God Committee." A famous 1962 Life magazine article laid the horror bare: educated, well-meaning people weighing a candidate's church attendance, net worth, marital status, and number of dependents to decide, in effect, who deserved to keep breathing. It was rationing at its most naked, and it made the country deeply uncomfortable.

That discomfort became the political fuel for one of the strangest pieces of healthcare legislation ever enacted. As Congress debated the Social Security Amendments of 1972, advocates for kidney patients staged a now-legendary demonstration: a patient was reportedly dialyzed live before a congressional committee to dramatize what the machines could do. Tucked inside the sprawling bill that President Richard Nixon signed on October 30, 1972, was a provision — often referenced as Section 299I — that created the Medicare End-Stage Renal Disease Program.

The effect of that clause was radical and, to this day, singular. It granted automatic Medicare eligibility to virtually any American diagnosed with kidney failure requiring dialysis or a transplant — regardless of age, income, or work history. A 30-year-old warehouse worker with failed kidneys became a Medicare beneficiary overnight, decades before the program's normal age-65 threshold. End-stage renal disease remains, more than half a century later, the only disease-specific universal healthcare entitlement in the United States. There is no comparable federal guarantee for cancer, for heart disease, for diabetes. Only for kidneys.

Congress thought it was buying a modest program for perhaps ten thousand patients at a manageable cost. It was catastrophically wrong on both counts. The eligible population exploded as diabetes and hypertension — the two leading causes of kidney failure — swept through an aging, increasingly obese nation. What the law had actually done was conjure a market out of thin air. Overnight, a scarce clinical charity was transformed into an open-ended, federally guaranteed, multi-billion-dollar commercial opportunity with a guaranteed payer standing behind every patient. Where the God Committee had seen an impossible moral rationing problem, entrepreneurs saw an addressable market with the full faith and credit of the U.S. Treasury behind the invoice.

Private, for-profit operators rushed in to build clinics, and the multi-decade consolidation wave that followed would eventually produce the two giants that dominate the field today. The essential DNA of the dialysis business was set in that moment: it is a private enterprise built on top of a public entitlement, and its fortunes would forever be tethered to the political and fiscal whims of the government that pays most of its bills.

What Actually Happens in a Dialysis Chair

It is worth pausing on the mechanics, because the economics of this industry are downstream of the biology, and most investors have only the haziest sense of what dialysis is.

Healthy kidneys are, in effect, a continuously running filtration plant. They pull waste products, excess salt, and excess fluid out of the bloodstream twenty-four hours a day, and they help regulate blood pressure and red-blood-cell production along the way. When they fail — usually as the end stage of decades of diabetes or high blood pressure — the toxins begin accumulating in the blood, fluid backs up into the lungs and tissues, and without intervention the patient dies within days to weeks.

Hemodialysis, the dominant modality, replaces that plant with an external machine. A vascular access point is surgically created in the patient's arm, blood is drawn out through a tube, passed across a semi-permeable membrane inside a filter called a dialyzer, and returned. Think of it as a mechanical laundry cycle for the bloodstream: the impurities diffuse across the membrane into a dialysate fluid, and the cleaned blood goes home. It takes roughly four hours, three times a week, forever, and it is exhausting. Patients frequently describe the hours after a session as feeling wrung out — hence the industry's persistent problem with "missed treatments," a metric that turns out to be an early warning signal for mortality.

Peritoneal dialysis, the main home modality, works on a different and more elegant principle: instead of routing blood through an external filter, fluid is cycled through the patient's own abdominal cavity, using the natural lining of the abdomen as the membrane. It can be done overnight while the patient sleeps, at home, with a machine roughly the size of a carry-on suitcase. This is why home dialysis is such a strategic prize — it converts a real-estate-and-labor-intensive service into something closer to a device-and-logistics business.

The other structural fact to hold onto is that dialysis is not a cure. It is life support. The only exit ramps are a kidney transplant — permanently constrained by organ supply — or death. Five-year survival on dialysis has historically been grim by the standards of most chronic conditions, which means the patient base has significant annual turnover and must be continuously replenished from the upstream chronic-kidney-disease population. That replenishment dynamic is the pipeline that the GLP-1 debate is ultimately about.

From Cost-Plus to the Bundle

The final piece of policy architecture arrived much later. For decades, Medicare paid dialysis providers a base rate for the treatment itself and then separately reimbursed the injectable drugs administered during the session — anemia medications, iron, vitamin D analogues. That separate-billing structure created an obvious and enormously consequential incentive: drugs became a profit center, and the more of them a clinic administered, the more it earned. Anyone reading ahead can already see where that leads.

Beginning January 1, 2011, CMS overhauled the model with the ESRD Prospective Payment System — the "bundle" — which folded most of those drugs into a single, all-inclusive per-treatment payment.¹⁷ Overnight, drugs flipped from a revenue line to a cost line, and providers were suddenly incentivized to use less medication rather than more. The bundle has been expanded periodically since; in 2025, oral phosphate binders were incorporated, which simultaneously raised DaVita's reported revenue per treatment and its pharmaceutical costs — a change that muddied year-over-year margin comparisons and required careful reading of the disclosures to see through.⁸

The lesson generalizes: in this industry, the government does not merely set the price, it periodically redesigns the shape of the payment, and each redesign redistributes profit pools overnight. That tether would nearly strangle one of the industry's largest players three decades after the founding legislation.

↑ Back to Top

III. Total Renal Care on the Brink: Enter Kent Thiry, the "Musketeer Mayor"

By the late 1990s, one of those roll-ups had grown fast and broken badly. It was called Total Renal Care, and it was dying. The company had bolted together a sprawling collection of clinics through a debt-fueled acquisition spree, and the machine underneath could not keep up. TRC could not reliably track its own clinical outcomes. It could not correctly bill or collect from insurers, which meant cash — its only lifeblood — arrived late or not at all. Accounting restatements loomed. Medicare billing investigations circled. In 1999 the company posted a loss of $147.3 million on revenue of about $1.45 billion, and its stock had collapsed toward penny-stock territory.⁵ It was, by any honest reckoning, a candidate for bankruptcy court.

In October 1999, the board reached for an unlikely savior. Kent Thiry had been about to take six months off to be with his family. A former Bain & Company consultant with a Harvard MBA and a stint running the dialysis firm Vivra, Thiry was intense, theatrical, and utterly convinced that culture — not spreadsheets alone — was the lever that moved companies. The board persuaded him to shelve the sabbatical and take the wheel of a sinking ship, naming him chairman and CEO.⁵⁶

What Thiry did next has become a genuine case study in business schools, admired and mocked in roughly equal measure. Rather than run a conventional turnaround of cost cuts and restructuring memos, he re-engineered the company's identity from the ground up. He declared that Total Renal Care was not a company at all but a "Village." Employees became "citizens." The head office became "Casa DaVita." Thiry himself was not the CEO but the "Mayor" — and at the enormous employee rallies he convened, which he called DaVita Academies, he would take the stage costumed as d'Artagnan of The Three Musketeers, in cape and plumed hat, brandishing a sword and leading thousands of citizens in a call-and-response chant of the Musketeer creed: "One for all, and all for one!"⁶ A bronze bell was installed to be rung in celebration of clinical milestones. Skeptics found the whole thing cultish, faintly absurd, and impossible to imagine at a serious medical company.

Here is the part the pageantry obscured, and the part that matters for an investor. Behind the costume was a ferociously disciplined operator. Thiry understood that in a business where the government sets your price, the only variables you control are cost, quality, and collection — and that all three depend on getting tens of thousands of frontline workers to execute the same protocol the same way in thousands of locations. The theater was a delivery mechanism for standardization. Thiry rebuilt the billing and collections engine so cash actually arrived. He standardized clinical protocols to drive down patient mortality, and he tied executive compensation to patient survival and treatment adherence — an unusually direct alignment of pay with the thing the business was supposedly for. In 2000, he rechristened the company DaVita, from the Italian for "he/she gives life."⁶

The Substance Behind the Spectacle

Three specific operating decisions deserve more attention than the costumes, because they are what actually produced the numbers.

The first was fixing the cash cycle. In a business where a single payer — the federal government — accounts for the majority of claims and where commercial claims run through a maze of plan-specific rules, the revenue-cycle function is not back-office administration; it is the difference between solvency and insolvency. Total Renal Care had been delivering treatments it could not bill and billing claims it could not collect. Rebuilding that machinery was unglamorous, invisible to patients, and probably the single highest-return project Thiry undertook.

The second was clinical standardization tied directly to compensation. Thiry made patient survival and treatment adherence explicit inputs into executive bonuses. This is rarer than it sounds. Most healthcare companies talk about quality; comparatively few make it a line item in the pay of the people who allocate capital. The mechanism worked because it aligned the operating machine with something that was, conveniently, also profitable — a patient who stays alive and shows up three times a week is both a better clinical outcome and a more valuable revenue stream. Alignment is easiest when interests genuinely coincide, and here they did.

The third was density. Thiry understood that dialysis scale is local, not national. Being the largest operator in the country confers modest purchasing leverage; being the dominant operator within a single metropolitan area confers real advantages in nurse utilization, float staffing across nearby clinics, physician relationships, and negotiating position with regional commercial payers. The acquisition strategy that followed the turnaround was accordingly about filling in maps, not planting flags. That distinction — local density over national footprint — is the single most important thing to understand about why this industry consolidated into two players rather than ten.

The results were real, and they were not a mirage of accounting. By 2004, the $147.3 million loss had become net income of roughly $222 million on revenue of about $2.3 billion; turnover had fallen sharply and clinical outcomes had improved.⁵ A company that had been left for dead was now generating the cash flow it would need to go on the offensive. The independent read on Thiry is genuinely mixed, and it is worth holding both halves at once: the culture demonstrably rescued the company and produced measurably better patient survival, and — as the later scandals would show — that same all-consuming, us-against-the-world Village ideology may have blinded the organization to how aggressively it was pushing on the boundaries of its billing. For now, though, the Village was ascendant, and its next act was to turn survival into dominance by mastering the one number that governs everything in dialysis: the payer mix.

↑ Back to Top

IV. Squeezing the Lemon: The Unit Economics of the "Payer Mix"

To understand why DaVita is profitable at all, you have to understand a piece of economic jiu-jitsu that would be illegal in most industries and is the entire game in this one. Start with the segment map, because it tells you immediately where to look. In fiscal 2025, of DaVita's $13.643 billion in consolidated revenue, the U.S. dialysis business generated $11.793 billion — about 86% of the top line — and produced $2.084 billion of operating income, which is actually more than the company's total consolidated operating income of $2.044 billion once corporate overhead is netted out.²³ Everything else is a rounding error by comparison: the International segment contributed $89 million of operating income across roughly 585 clinics in 14 countries, and the Integrated Kidney Care unit — which we will return to as a strategic hedge — contributed just $22 million.² So when you analyze DaVita, you are, to a first approximation, analyzing a single business: American outpatient dialysis. Everything else is a sideshow.

That core business is a duopoly, and a remarkably stable one. DaVita runs roughly 2,660 U.S. dialysis centers and serves a domestic census of around 200,000 patients; Fresenius Medical Care runs a comparable number; and between them the two companies control close to 80% of the market.³ There is one structural difference worth flagging: Fresenius is vertically integrated, manufacturing its own dialysis machines and home-hemodialysis systems, while DaVita is a pure services provider that buys its equipment and consumables from third parties — including, in a delicious twist, from Fresenius and from Baxter. DaVita is the operator; Fresenius is the operator and the arms dealer.

That concentration is not merely a curiosity of industry structure; academic and economic analysis has repeatedly found that dialysis is now among the most concentrated sectors in all of American healthcare, and that commercial prices run materially higher in markets where the two firms face little competition.¹⁸ This is the uncomfortable flip side of the moat: the same market structure that makes DaVita a durable business is, from a policy standpoint, an argument for intervention. Investors owning a duopolist in an essential, publicly subsidized service should understand that they are, in part, holding a position on political forbearance.

The international business deserves a brief note, because it is the only place DaVita can still grow by building and buying without antitrust friction. The segment operated roughly 585 to 596 centers across 14 countries at the turn of 2026, and its scale was meaningfully enlarged by an unusual transaction: in 2024 DaVita agreed to acquire Fresenius Medical Care's dialysis clinic operations in Brazil, Colombia, Chile, and Ecuador — the two duopolists trading assets in markets where the competitive stakes were lower.[^22]¹¹ Management has framed international as contributing roughly a percentage point of enterprise operating income growth, split between organic expansion and acquisitions.¹⁵ It is a real option, but on $89 million of operating income against a $2 billion consolidated base, it is not yet a thesis. It is a hedge with a long fuse.

Now the jiu-jitsu. Roughly 89% of DaVita's patients are covered by government programs, overwhelmingly traditional Medicare.⁷ And here is the dirty secret of the industry: on a fully loaded basis, Medicare frequently pays less than it costs to deliver a treatment. In 2025 DaVita's average U.S. patient-care cost was running around $280 per treatment,⁸ while government reimbursement per treatment sits in the low-to-mid hundreds — a spread that, after clinical labor, drugs, real estate, and overhead, can turn the government book of business slightly upside down. If DaVita only had Medicare patients, it would not be a business at all. It would be a charity slowly going bankrupt.

The rescue comes from the other roughly 11% of patients — the ones with commercial, employer-sponsored insurance.⁷ Commercial plans reimburse at multiples of the Medicare rate, often several times higher per session. The math is stark: commercial payers represented about 32% of DaVita's total revenue in 2025 despite covering only about one in nine patients,⁷ and the profit concentration is even more extreme than that revenue skew implies. Because the government book roughly breaks even or loses money, essentially all of DaVita's operating profit is generated by that thin commercial slice. Blended average U.S. dialysis revenue per treatment ran about $410 in 2025, up nearly 5% year over year⁹ — but that blended figure hides two wildly different populations stacked on top of each other: a huge, break-even government majority and a small, hugely profitable commercial minority.

What locks the profit in for a defined window is a piece of federal plumbing called the Coordination of Benefits rule. When a working person with employer insurance develops kidney failure, their commercial plan is legally required to remain the primary payer for the first 30 months before Medicare takes over. For those 30 months, DaVita gets to bill the high commercial rate. After that, the patient rolls onto Medicare and the economics on that individual collapse toward break-even. So the entire investable question in dialysis compresses down to a single discipline: acquire commercial patients, retain them, keep them clinically stable and in-network, and harvest as much of that golden 30-month window as possible. This is what management means, in its more clinical euphemisms, by "payer mix" and "commercial mix."

The Cost Side: Why This Is Really a Labor Business

Flip to the expense line and the model becomes even clearer. In the fourth quarter of 2025, DaVita's patient-care cost per treatment was about $280, against revenue per treatment of roughly $423 — a gross spread of about $143 per session before any corporate overhead, G&A, interest, or depreciation on the clinic estate.³ That $280 is dominated by two things: people and supplies.

The people are the constraint. Every in-center treatment requires licensed clinical staff — registered nurses and patient-care technicians — working within regulated staffing ratios, on shifts that typically run from before dawn into the evening to cycle three or four patient groups through the same chairs each day. Chair utilization is the closest thing dialysis has to a hotel's occupancy rate: fill the chairs across more shifts and the fixed cost of the building and the machines is spread thinner. Fail to fill them, or fail to staff the later shifts because you cannot hire nurses, and the economics of that clinic deteriorate quickly.

This is why wage inflation is so uniquely damaging here compared with most businesses. A restaurant facing higher labor costs raises menu prices. A software company facing higher engineering costs raises subscription prices. DaVita, facing higher nursing costs on roughly 89% of its volume, can do essentially nothing, because that price is set by an act of Congress and adjusted annually by an agency using its own inflation formula. The company's ability to protect margins therefore reduces to three levers: negotiate harder on supplies, engineer patients into cheaper settings (home), and grow the commercial slice. Each of those is a strategy we will encounter again.

Reading the Blended Number Correctly

One practical warning for anyone tracking this company. The headline metric management reports — average U.S. dialysis revenue per treatment, around $410 for 2025 — is a blend that can move for reasons that have nothing to do with underlying pricing power. It rises when commercial mix improves. It also rises when CMS folds new drugs into the bundle, as happened with phosphate binders in 2025, even though the offsetting cost rose in lockstep and the margin contribution was minimal.⁸ It falls when commercial patients age off their 30-month window faster than new ones enter.

In other words, revenue per treatment is a composite of at least three distinct forces — payer mix, policy design, and negotiated rates — and reading a year-over-year increase as evidence of pricing power is a common and expensive mistake. The metric that actually matters is the commercial mix underneath it.

For an investor, three uncomfortable implications follow. First, the profitability of this company is astonishingly fragile — it rests on a thin, legally defined margin that a court ruling or a benefits-design change could compress. Second, the incentive structure this creates is genuinely perverse: management is rewarded for maximizing revenue from the sickest, best-insured patients during a narrow window, which is a recipe for the kind of aggressive behavior that invites regulators. And third, it explains why the whole industry fights so ferociously — in courtrooms, in Congress, and in state insurance regulations — to defend that commercial cross-subsidy. It is not a side issue. It is the business. And in the decade after the turnaround, the temptation baked into that structure would pull DaVita across some very bright legal lines.

↑ Back to Top

V. The Dark Underbelly of the Village: Whistleblowers, Kickbacks, and Federal Settlements

The extreme margin pressure of the government book and the intoxicating profitability of the commercial book combined to create one of the most dangerous incentive structures in American healthcare. When a business loses money on 89% of its customers and makes all of its money on the other 11%, the pressure to squeeze every legal — and sometimes illegal — dollar out of the system becomes immense. Under Thiry's leadership, DaVita repeatedly pushed past the boundary, and a series of insiders repeatedly blew the whistle.

The first mechanism was referrals. In American nephrology, the doctor controls the patient. A kidney patient goes wherever their nephrologist sends them, which makes the referring physician the single most valuable relationship in the entire model. DaVita understood this perfectly, and according to the federal government it built a machine to exploit it. A former DaVita financial analyst named David Barbetta filed a whistleblower suit alleging a systematic kickback scheme: DaVita would offer nephrologists cheap, lucrative equity stakes in local joint-venture clinics, and in exchange those doctors were effectively bound to steer their patients into DaVita facilities. The company allegedly used sophisticated financial models to identify which doctors' referral streams were worth capturing and priced the equity to make it irresistible. In October 2014, DaVita agreed to pay $350 million to resolve the civil claims, with additional forfeitures bringing the total resolution to roughly $389 million.[^11]

The second mechanism was even more brazen, and it targeted the taxpayer directly. Whistleblowers Dr. Alon Vainer, a nephrologist, and nurse Daniel Barbir exposed what came to be known as the "dosing grid" scheme. The drugs involved were Zemplar and Venofer — expensive medications for the anemia and bone disease that plague dialysis patients — and they came in single-use vials. Medicare, crucially, reimbursed based on the amount of drug drawn from a vial, and would pay for the full vial even if only part was used. The whistleblowers alleged that DaVita corporate management designed clinical protocols that deliberately called for oversized vials and dosing schedules engineered to leave expensive medicine left over — medicine that was then thrown away, with the discarded portion billed to the federal government. It was, in essence, a scheme to manufacture waste because the waste was profitable. In May 2015, DaVita agreed to pay $450 million to settle those allegations.[^12] An earlier matter in 2012 saw the company pay a further reported $55 million over allegations tied to overbilling Medicare for the anemia drug Epogen.

Add it up and, in the space of a few years, DaVita paid out close to $900 million to settle allegations that spanned kickbacks and taxpayer fraud. The company admitted no wrongdoing in the customary fashion, and — this is important for a balanced read — it simultaneously maintained genuinely strong average clinical-quality scores throughout. Patients were, on the metrics, well cared for. But the pattern is the analytical point, and it is not flattering. A company that treats nine-figure fraud settlements as a recurring line item is telling you something about how it views the boundary between aggressive optimization and lawbreaking. The Village's fierce, insular, us-versus-the-world culture — the very thing that rescued the company — appears to have doubled as an ideological shield, a mindset in which pushing the government-reimbursement system to and past its limits could feel like winning rather than cheating.

Myth vs. Reality: "It Was All Just Regulatory Ambiguity"

The sympathetic reading of these episodes, which DaVita and its defenders have advanced over the years, is that healthcare billing rules are genuinely byzantine, that reasonable parties disagree, that settlements are routine in the sector, and that the company never admitted wrongdoing. There is a kernel of truth in that. Federal healthcare fraud enforcement does sweep in ambiguous conduct, and companies frequently settle to avoid the existential risk of exclusion from Medicare rather than because they believe they are guilty.

But the specifics here strain the ambiguity defense. Designing a dosing grid that produces expensive leftover medicine, and doing so at corporate level as a protocol pushed down to clinics, is not the kind of thing that happens by accident in the fog of regulatory complexity. Neither is building financial models to price physician equity stakes against the value of their referral streams. These were engineered systems, not clerical errors. The honest characterization is that DaVita operated in a gray zone by design and calibrated how far into it to go — and that the calibration was occasionally wrong by several hundred million dollars.

There is also a second-order point about the drug-waste case that connects directly to the policy history. The dosing-grid scheme was only possible because Medicare, at the time, reimbursed injectable drugs separately from the treatment itself. When CMS moved to the bundled payment system, that particular arbitrage evaporated overnight — not because anyone's ethics improved but because the incentive was removed.¹⁷ It is a clean demonstration of a general principle: in reimbursement-driven industries, behavior follows payment design far more reliably than it follows compliance training.

For investors, the lesson is not simply "this company broke the law." It is that the settlements were rational within the model. When the core business loses money and the commercial subsidy is under permanent threat, regulatory arbitrage becomes a tempting third profit center, and the fines become a tax on a strategy rather than a deterrent against it. That is a management-credibility fact worth carrying forward. It is also, tellingly, exactly the kind of durable, cash-generative, hard-to-disrupt franchise that attracts a certain kind of patient capital. Because right as the settlements were mounting, the most famous investor in the world was quietly buying.

↑ Back to Top

VI. Berkshire Hathaway Enters "The Village": Weschler's Moat & The Share Cannibalization Playbook

The Berkshire Hathaway position in DaVita did not begin with Warren Buffett. It began with Ted Weschler, a low-profile Charlottesville-based hedge fund manager who, before joining Berkshire, had built a concentrated, deeply researched book of the kind of unglamorous, cash-gushing businesses Buffett prizes. Weschler famously paid over $5 million across two charity auctions for lunch with Buffett; the two hit it off, and in 2011 Weschler was hired to help manage Berkshire's investment portfolio. He brought DaVita with him, and once inside Berkshire the position grew until the conglomerate became the company's largest shareholder.¹

Why would the ultimate quality-and-moat investors want a business steeped in fraud settlements and dependent on a fragile subsidy? Because the moat, viewed coldly, is one of the widest in healthcare. Consider switching costs. A dialysis patient must physically appear at a specific clinic three times a week for the rest of their life, form relationships with the nurses who keep them alive, and organize their entire existence — work, transport, family — around a fixed treatment schedule at a location near home. They almost never switch providers; the friction is not a marketing inconvenience but a life-structuring reality. Consider demand elasticity. If a dialysis patient stops showing up, they die within roughly two weeks. This is demand utterly immune to recession, inflation, or shifting consumer taste — the most inelastic, non-discretionary consumption in the entire economy. And consider entry barriers: in many states, opening a new clinic requires navigating "Certificate of Need" regulations, and the two incumbents already blanket the map. A new entrant faces both a regulatory gauntlet and a duopoly that can out-scale it on day one.

But the moat alone does not explain the compounding. For that you need the financial engineering, and it is a masterclass in what to do when you own a wonderful business that cannot grow. Here was DaVita's dilemma: it threw off enormous free cash flow, but it could not reinvest that cash into building new clinics without triggering the Federal Trade Commission, because it and Fresenius already controlled most of the market. Organic growth was capped at roughly the underlying growth rate of the diabetic and obese population — call it 1–2% a year in a good year. A gusher of cash and nowhere productive to put it.

So management turned the cash gusher on its own share count. Over the past decade, DaVita has directed the overwhelming majority of its free cash flow into repurchasing its own stock, systematically retiring shares year after year. The outstanding count fell from roughly 93 million shares a decade ago to around 66 million by early 2026.¹⁰ Think about what that does. Even if total profit merely holds flat, dividing that profit across a shrinking number of shares mechanically drives earnings per share upward. In 2025 the company bought back 12.7 million shares at an average price of about $140, roughly $1.8 billion of repurchases in a single year,³ and it continued at pace into 2026, retiring another 3.0 million shares in the first quarter alone.¹¹ By retiring close to a third of its equity over a decade, DaVita manufactured consistent double-digit EPS growth out of a business whose revenue barely moved.

The elegance — and the risk — of this compounds with the Berkshire position. Because Berkshire holds a roughly static block of shares while the total shrinks, its percentage ownership rises automatically, without Berkshire spending another dollar. The stake climbed toward 45% purely through the denominator shrinking beneath it. The relationship became so mechanically potent that DaVita and Berkshire signed a formal repurchase agreement under which the company buys shares back from Berkshire on a schedule specifically to keep its beneficial ownership from breaching 45%.¹¹² It is one of the more unusual capital-allocation arrangements in public markets: a company and its largest holder contractually coordinating buybacks so the holder does not accidentally end up owning half the enterprise.

The Arithmetic, Made Simple

Strip the mechanism to its bones, because it is the heart of the investment case and it is often described imprecisely.

Imagine a business earning $1 billion a year with 100 million shares outstanding: $10 per share. The business does not grow at all — revenue is flat, profit is flat, forever. Now suppose it spends its entire cash flow buying back 4% of its shares annually. After a decade, the share count is roughly 66 million, and the same unchanged $1 billion of profit now translates to about $15 per share. The owner of a share has seen their claim on the business grow by half, while the business itself did precisely nothing.

That is DaVita in caricature, and it explains a stat that otherwise looks like a typo. For 2025 the company reported adjusted operating income of $2.094 billion — a modest advance — yet guided 2026 adjusted earnings per share to a midpoint representing roughly a third more than the prior year.²¹⁵ Almost none of that jump comes from the business getting bigger. It comes from the denominator getting smaller, plus the removal of a drag from losses at Mozarc Medical, the home-dialysis-technology joint venture DaVita holds with Medtronic, whose losses had been flowing through DaVita's results.¹⁵

This is a genuine and repeatable form of value creation — retiring shares below intrinsic value transfers wealth to the remaining holders — but it is important to be precise about what it is and is not. It is not growth. A company cannot buy back its way to a larger business, and per-share compounding that depends entirely on shrinkage has a natural ceiling: eventually there are no shares left to retire, or the balance sheet cannot support more debt, or the price rises to a level where repurchases stop being accretive. Management's own disclosure of the buyback average price is worth watching for exactly this reason. In 2025, DaVita repurchased at an average of about $140 a share; in the first quarter of 2026 the average was about $134, and in the weeks immediately after year-end it bought at roughly $121.³¹¹ Buying more aggressively as the price falls is what a disciplined repurchaser should do, and to management's credit that is broadly the pattern the disclosures show.

Now for the neutral investor's warning, because the buyback engine is genuinely double-edged. Aggressive repurchases funded largely by debt — DaVita ran net leverage around 3.3 times EBITDA at the end of 2025, near the middle of its 3.0–3.5x target range¹⁰ — are magnificent when the underlying cash flows are stable and the terminal value of the clinic network is secure. But buybacks also lever the equity to the downside. If the terminal value of those physical clinics is impaired by a drug (GLP-1s) or a court (Marietta), a shrunken share count sitting atop an elevated debt load can turn a moderate operating decline into a severe equity one. Financial engineering does not create value out of thin air; it concentrates whatever value — or risk — the operating business actually has. Which raises the obvious question: with a fortress balance sheet and nowhere to build, why didn't DaVita simply keep buying back stock all along? For seven expensive years, it tried something else instead.

↑ Back to Top

VII. The DMG Diversion: HealthCare Partners and the $4.4B Strategic Blunder

By 2012, Kent Thiry had a nagging fear, and it was the right fear for the wrong solution. He looked at his business — utterly dependent on the commercial cross-subsidy, forever one regulatory ruling away from a margin shock — and concluded that DaVita needed to diversify away from pure dialysis before Washington came for the golden window. The instinct was sound. The execution was a decade-consuming mistake.

In May 2012, DaVita agreed to acquire HealthCare Partners, one of the largest operators of physician groups and managed-care networks in the country, for approximately $4.42 billion — about $3.66 billion in cash plus roughly 9.38 million DaVita shares valued at $758 million.¹³ The company renamed itself DaVita HealthCare Partners Inc., a rebranding meant to signal a grander ambition. The strategic thesis was fashionable and, on paper, coherent: instead of merely billing for individual dialysis sessions, DaVita would own primary-care physician groups, urgent-care centers, and specialty clinics, and take on full financial risk for patients' total health — especially in the lucrative, fast-growing Medicare Advantage market, where a provider that keeps patients healthy and out of the hospital gets to keep the savings. Own the whole patient, manage the whole risk, capture the whole reward.

The problem was that running a physician network is almost nothing like running a dialysis chain, and DaVita had confused the two. Its core competence was industrial standardization: take a narrow, repetitive clinical procedure and execute it identically across thousands of locations with tight cost control. HealthCare Partners was the opposite kind of business — thousands of relatively autonomous primary-care doctors making countless individualized judgment calls, embedded in a bewildering web of multi-payer insurance contracts where medical costs could spike unpredictably and eat an entire year's margin. The assembly-line playbook did not transfer. Integration was poor, medical-cost trends ran hot, and the division drew its own regulatory billing scrutiny. Rather than serving as a stabilizing hedge, DMG became a persistent drag on consolidated margins and returns on capital.

After roughly seven years of struggle, DaVita gave up. It agreed to sell the division — by then renamed DaVita Medical Group — to UnitedHealth Group's Optum. The deal had originally been announced in December 2017 at $4.9 billion, but the price was renegotiated downward, and to clear the Federal Trade Commission the parties had to divest assets in Nevada; the sale finally closed in June 2019 at roughly $4.34 billion.¹⁴

Tally the scorecard with an unsentimental eye. DaVita paid $4.42 billion in 2012, poured additional capital expenditure into the business for seven years, and sold it for $4.34 billion in 2019 — a headline round-trip that, once you account for the intervening investment and the opportunity cost, represents meaningful destruction of capital and, arguably worse, a wasted decade of senior-management attention.¹³¹⁴ This is the classic "diworsification" trap that skeptical investors watch for: a cash-rich company in a no-growth core, unable to reinvest at home, reaching into an adjacent business it does not understand and destroying value in the name of strategic defense. For a management team that would later ask investors to trust its judgment on capital allocation, the HCP episode is a permanent entry on the credibility ledger.

There was, however, one genuine silver lining, and it set up the next chapter. The Optum sale delivered a mountain of cash back onto DaVita's balance sheet at exactly the moment the company was refocusing on its core. That cash supercharged the share-cannibalization program we just examined — the diversification failure, ironically, funded the financial-engineering success. And it happened just as the Mayor prepared to hang up his sword.

↑ Back to Top

VIII. The Modern Transition: Javier Rodriguez and the Push for Home Dialysis

Kent Thiry's exit in 2019 was not the triumphant curtain call a two-decade turnaround artist might have scripted. He stepped down as chairman and CEO amid mounting federal scrutiny of "no-poach" agreements — arrangements in which DaVita allegedly agreed with other companies not to solicit each other's senior employees. The matter escalated into a criminal antitrust prosecution of the company and Thiry personally; in 2022, a Colorado jury acquitted both of the labor-market conspiracy charges. But the spectacle of a former CEO on trial, whatever the verdict, marked a decisive tonal break from the Village's swashbuckling self-image.

His successor was his opposite in temperament. Javier Rodriguez, a roughly two-decade veteran of the company who had run DaVita Kidney Care, was elevated to CEO of the consolidated enterprise. Where Thiry was theatrical, Rodriguez was an operator — quiet, execution-focused, allergic to spectacle. The Musketeer costumes and the cavalry-charge rallies were retired. There would be no more swords. There would instead be two structural crises that no amount of pageantry could chant away.

The first was labor. Outpatient dialysis is punishingly labor-intensive, dependent on specialized registered nurses and patient-care technicians who must be trained, licensed, and retained. The post-COVID nursing shortage and the wage inflation that followed hit DaVita's cost structure directly, forcing higher wages, expensive reliance on temporary travel nurses, and a redesign of clinical scheduling. In a business where the government caps your price, every dollar of unavoidable wage inflation flows straight out of operating income — there is no ability to simply pass it through to Medicare. Clinical labor and supply costs remain, to this day, the single most important controllable variable in the model; in 2025, patient-care costs per treatment rose nearly 6% year over year, roughly half of that driven by the incorporation of phosphate-binder drugs into the Medicare payment bundle and much of the rest by wages and supplies.⁸¹⁵

The second crisis was, in an odd way, an opportunity dressed as a mandate. In July 2019, the Trump administration issued the Advancing American Kidney Health executive order, which reoriented Medicare's reimbursement models to aggressively favor home-based dialysis — peritoneal dialysis and home hemodialysis — over traditional in-center treatment. The policy logic was that home dialysis is often better for patients and cheaper for the system. For DaVita, the strategic logic was even more compelling than the clinical one: home dialysis strips out the most expensive parts of the in-center model. It reduces the need for physical clinic real estate, utilities, and on-site nursing labor, shifting the treatment burden onto the patient and a support system in their own living room. In a world of relentless wage and rent inflation, moving a patient home is a margin-defense maneuver as much as a clinical-quality one.

Rodriguez leaned in hard, and here the neutral read matters. Management has consistently framed home dialysis as a core long-term margin and growth driver, and it has publicly targeted moving well past a quarter of its patient base onto home modalities over time. The company has genuinely grown its home census and remains, alongside Fresenius, one of the two largest home-dialysis providers in the country. But the transition is slower and harder than the strategy decks imply: home therapies require careful patient selection, extensive training, higher near-term dropout risk, and a support infrastructure that is itself costly to build. Home dialysis is a real margin lever, but it is a multi-year one, and it is not a switch management can flip on demand. The honest scorecard is "meaningful progress, target not yet reached."

The Volume Problem Nobody Modeled

There is a third crisis that emerged later and that management has been notably more candid about than one might expect: DaVita's U.S. treatment volume has stopped growing.

For most of the company's history, volume growth was the boring, dependable input to every model — the diabetic and obese population expanded, kidneys failed at a predictable rate, and the census ticked upward by one or two percent a year. Then it stopped. In 2025, DaVita's normalized non-acquired treatment growth was negative, at about minus 0.9% for the year, with U.S. treatments totaling 28.73 million and average treatments per day of roughly 91,800.³ By the first quarter of 2026, treatments per day were essentially flat sequentially at about 91,650, with the company managing only a modest improvement on a normalized-day basis.¹¹

Management has attributed the shortfall to a cluster of specific, largely non-structural factors: elevated patient mortality in the post-pandemic period, a historically severe flu season, a hurricane-disrupted supply chain, and the operational fallout from a cybersecurity incident.³¹⁵ On the Q4 2025 call, CFO Joel Ackerman noted that missed treatment rates had not materially worsened year over year, and that clinical leadership sees a lagged correlation between missed treatments and mortality.⁸

The company's response has been to name four specific clinical initiatives it believes will restore growth: pushing flu vaccination rates back above 90% from roughly 80%; driving GLP-1 adoption and adherence among its own dialysis patients for the cardiovascular benefit; deploying advanced dialysis technologies such as medium cut-off dialyzers; and a home-health partnership with Elara Caring aimed at end-stage kidney patients, backed by a $200 million minority investment alongside Ares.¹⁵ Rodriguez told analysts the company believes it is "on a path back to at least 2% volume growth," while explicitly conceding that the benefits arrive over a multi-year horizon extending toward 2029.¹⁵

Assess that honestly and you get a genuinely mixed credibility read. On the positive side: the diagnosis is specific rather than hand-waving, the initiatives are concrete and measurable, the timeline is stated plainly rather than buried, and management is not pretending the problem away — a company embracing the drug the market fears is at least not in denial. On the cautious side: a multi-year promise that pays off in 2029 is, by construction, one that cannot be falsified for several years, and elevated mortality is precisely the kind of explanation that could be describing either a temporary post-COVID cohort effect or the leading edge of a structural change in the patient pipeline. This is the single most important open question in the DaVita story, and it is the one where investors should be least willing to accept management's framing on faith. Which is exactly where the market's fears about a class of diabetes drugs come crashing in.

↑ Back to Top

IX. The Existential Duopoly: GLP-1s, Marietta, and the Future of Kidney Care

On October 10, 2023, a single press release from a Danish drugmaker wiped out roughly a fifth of DaVita's market value in a matter of hours. Novo Nordisk announced that it was halting its FLOW trial early. FLOW had been testing whether semaglutide — the active ingredient in Ozempic and Wegovy — could slow kidney disease in patients with type 2 diabetes and chronic kidney disease. The trial was stopped not because it failed but because it succeeded too well: an independent monitoring committee found the drug was reducing the risk of kidney-disease progression and cardiovascular-or-kidney death by 24%, a result so decisive that keeping patients on placebo became ethically untenable.⁴ DaVita's stock, along with Fresenius's and other dialysis-linked names, fell sharply that day as the market priced in an existential fear.¹⁶

The bear thesis was brutally simple. Dialysis is the terminal stage of a disease pipeline: obesity and diabetes damage kidneys, kidneys decline over years, and eventually they fail and the patient needs dialysis. If a cheap, wildly popular class of drugs bends that curve — keeping kidneys healthier for longer and thinning the flow of patients reaching end-stage failure — then the pipeline feeding DaVita's clinics shrinks, and the terminal value of a nationwide network of physical dialysis centers deflates. The clinics become stranded assets in slow motion.

Management, and a number of clinical analysts, countered with a genuinely provocative argument they call "survival expansion," and it deserves to be laid out honestly rather than dismissed. The counter-thesis rests on a grim epidemiological fact: the leading cause of death for people with advanced chronic kidney disease is not kidney failure at all — it is cardiovascular disease. A large share of these patients die of heart attacks or strokes before their kidneys ever deteriorate to the point of needing dialysis. GLP-1 drugs are powerfully cardioprotective. So, the argument goes, by preventing the heart attacks that would otherwise kill these patients early, GLP-1s allow more of them to survive long enough to eventually reach end-stage renal disease. Counterintuitively, keeping high-risk diabetics alive could expand, rather than shrink, the long-run dialysis census. On the Q4 2025 earnings call in February 2026, Rodriguez pointed to a growing body of evidence that GLP-1s reduce major adverse cardiac events and mortality in dialysis patients, and framed the company as actively working with physicians to encourage adoption among its patients rather than fearing it.¹⁵

An independent observer has to hold this thesis at arm's length. It is plausible, it is supported by real clinical logic, and management's willingness to embrace rather than deny the drugs is a point in its favor. But it is also, for now, a hypothesis about a multi-decade demographic flow, not a proven fact — and it is exactly the kind of comforting narrative a threatened incumbent would want to be true. The most honest statement is that the net long-term effect of GLP-1s on the dialysis population is genuinely uncertain, with credible mechanisms pointing in both directions, and that the ultimate answer will play out over ten to twenty years, not two.

If GLP-1s threaten the supply of patients, the Supreme Court threatened the profitability of the ones DaVita already has. In Marietta Memorial Hospital v. DaVita, decided 7–2 on June 21, 2022, in an opinion by Justice Kavanaugh, the Court ruled that an employer health plan does not violate the Medicare Secondary Payer statute merely by offering limited dialysis benefits — so long as those limits apply uniformly to all plan members rather than singling out ESRD patients.[^5] Justices Kagan and Sotomayor dissented, warning that the ruling created an obvious roadmap: an employer can gut dialysis coverage for everyone (knowing that essentially only ESRD patients use it), push those patients onto Medicare early, and legally escape the cross-subsidy — all without technically discriminating against the kidney-disease population.

The economic risk here is precise and it strikes at the heart of Section IV's payer-mix engine. If self-insured employers broadly adopt "dialysis carve-outs" following the Marietta template, they can collapse the golden 30-month commercial window, forcing DaVita's most profitable patients onto break-even Medicare far sooner. Because essentially all of DaVita's profit lives in that commercial slice, even a modest erosion of commercial mix flows almost directly to operating income. Several years on from the ruling, the broad-based carve-out wave that bears feared has not materialized at scale — but it remains a live, structural overhang rather than a resolved question, and it is the single cleanest example of how a business built on regulatory arbitrage can be undone by a single change in the rules.

The Slower, Quieter Erosion

There is a subtler version of the payer-mix risk that gets less attention than Marietta and may matter more in the near term, because it operates through ordinary policy and macroeconomics rather than through litigation.

Commercial coverage for dialysis patients comes from two main sources: employer-sponsored plans and individual marketplace plans purchased under the Affordable Care Act. Both are sensitive to forces entirely outside DaVita's control. Employer coverage tracks the labor market — a patient who loses their job during a downturn may lose the coverage that makes them profitable. Marketplace coverage tracks subsidy policy, and here management flagged a specific, quantified headwind: roughly $40 million in 2026 from the expiration of enhanced premium tax credits, which had made marketplace plans meaningfully cheaper for lower-income enrollees.¹⁵ Ackerman noted that open enrollment had performed better than the company forecast and that dialysis patients tend to be unusually sophisticated about maintaining coverage — a plausible claim, given that these are people for whom insurance status is literally a survival variable, but also one that has not yet been tested through a full cycle of subsidy withdrawal.

There is a mirror-image dynamic on the government side worth noting for balance. Medicare Advantage plans have been permitted to enroll ESRD patients since 2021, which shifted a growing share of the government book from traditional fee-for-service Medicare into privately administered plans that negotiate their own rates. Management pointed analysts toward a roughly 6% rate increase for the ESRD population in the 2027 Medicare Advantage framework, framing it as a correction of prior underfunding that could encourage plans to expand in this population.¹⁵ That is a genuine potential positive, and it complicates the simple "government book loses money" story: the government book is itself fragmenting into segments with different economics.

The net picture is that DaVita's payer mix is being pulled by at least four independent forces at once — court-enabled employer carve-outs, marketplace subsidy policy, the labor market, and the migration into Medicare Advantage. None is fully within management's control, and the interaction between them is why the commercial-mix metric deserves more attention than any other number the company reports.

The Hedge

DaVita's chosen defense against Marietta is the Integrated Kidney Care segment — the value-based unit that generated $542 million of revenue and reached its first full-year profitability of $22 million in 2025, ahead of the company's own target.²¹⁵ The strategic logic is elegant: rather than merely billing per session, IKC contracts with insurers to manage the total health of a kidney patient, sharing in the savings generated by keeping them out of the hospital. By 2025 IKC was managing roughly 66,000 patients in risk-based arrangements representing about $5.6 billion of annualized medical spend.³ If DaVita can make itself indispensable to payers as a total-cost-of-care partner — not just a dialysis vendor — it raises the cost and complexity of any employer trying to carve dialysis out, because DaVita is now woven into the payer's own economics. Whether IKC can scale into a genuine strategic moat or remains a small, hard-won profit center is one of the most important open questions in the entire investment case.

↑ Back to Top

X. Playbook: Business & Investing Lessons

Step back from the clinics and the courtrooms, and three durable lessons emerge from the DaVita story — lessons that generalize well beyond dialysis.

The first is the limit of regulatory arbitrage. DaVita is, at its foundation, a business that survives by cross-subsidizing a money-losing government service with hyper-inflated commercial pricing. That structure can be spectacularly profitable for a long time, but it is inherently brittle, because its profitability lives at the mercy of forces the company does not control: a CMS reimbursement update, a Supreme Court ruling, a change in employer benefit design. A moat made of regulation is only as wide as the regulators allow it to be, and it can be narrowed by a single vote — of a court, a Congress, or an agency. Investors in any business whose margins depend on a specific rule staying in place should ask constantly: what happens to the economics if the rule changes? For DaVita, the answer is genuinely severe, and the Marietta case is the proof of concept.

The second is the double-edged sword of financial engineering. DaVita's buyback machine is a textbook demonstration of how to compound per-share value in a no-growth, cash-generative duopoly — retiring a third of the shares turned flat revenue into years of double-digit EPS growth, and did so while automatically lifting Berkshire's stake toward its contractual cap. But the same mechanism cuts the other way. Buybacks funded by leverage magnify the equity's sensitivity to the operating business. If GLP-1s or Marietta impair the terminal value of the clinic network, a smaller share count sitting atop a 3.3x-levered balance sheet converts operating pain into amplified equity pain. Buybacks are a lever, not a shield; they concentrate outcomes, good and bad. And aggressive repurchases can flatter the reported EPS trend for years even as the underlying operating story quietly decays — which is precisely when investors should watch the operating metrics, not the per-share ones.

The third is the illusion, and the danger, of corporate culture. Kent Thiry's Village is genuine proof that an extreme, cult-like culture can align an organization, rescue a dying company, and drive measurable improvements in something as important as patient survival. Culture is not a soft luxury; here it was the operating system of a turnaround. But the DaVita story is also a warning that the same intense, insular, us-against-the-world ideology that binds a workforce together can blind it — that a company convinced of its own righteousness can drift into kickback schemes and taxpayer-billing games while still believing it wears the white hat. Strong culture and weak compliance are not opposites; in DaVita's case they appear to have grown from the same root. The tell for investors is behavior over time, and DaVita's recurring nine-figure settlements are the behavior that matters more than the mission statement.

↑ Back to Top

XI. Analysis, Bull vs. Bear, and Risk Radar

Hamilton Helmer's 7 Powers and Porter's Five Forces

Run DaVita through Hamilton Helmer's 7 Powers and the moat resolves into three concrete sources. Scale economies are high and, crucially, local: dialysis density within a metro area drives labor efficiency, nurse utilization, and clinical-coordination advantages that a subscale entrant cannot match, and the national duopoly means the incumbents can always out-scale a newcomer in any given market. Switching costs are extraordinarily high — arguably as high as in any consumer-facing business anywhere — because patients organize their survival around a specific clinic and specific caregivers three times a week, and simply do not leave. Process power is medium-to-high: two decades of clinical-protocol optimization, CMS and FDA compliance machinery, revenue-cycle sophistication, and specialized workforce management form an operational playbook that is genuinely hard and slow to replicate, even for a well-funded challenger.

Through Porter's Five Forces, the picture is a fortress with two cracks. Threat of new entrants: low, throttled by Certificate-of-Need regimes, capital intensity, and duopoly density. Rivalry: muted — DaVita and Fresenius compete more like a stable cartel than gladiators, which is precisely why regulators and academics describe the market as one of the most concentrated in all of healthcare. Supplier power: moderate and rising, given a specialized-nurse labor market with real bargaining power and an equipment supply chain that includes DaVita's own rival, Fresenius. Buyer power: this is the dangerous force — commercial payers and self-insured employers, newly armed by Marietta, are the buyers with both the incentive and now the legal means to attack the cross-subsidy. Substitutes: transplantation (supply-constrained by organ availability) and, newly, the pharmaceutical prevention represented by GLP-1s. The moat is deep against competitors and shallow against payers and drugs — and it is payers and drugs, not competitors, that constitute the actual threat.

The Three KPIs That Actually Matter

An investor tracking DaVita does not need a hundred metrics. Three carry most of the signal:

1. Commercial payer mix (%). The share of treatment volume paid by commercial insurers, historically hovering around 10–11% of patients but roughly a third of revenue. Because essentially all profit lives here, any sustained downward drift — whether from Marietta carve-outs, a weakening labor market that shifts patients off employer plans, or the expiration of enhanced ACA premium tax credits (a roughly $40 million headwind management flagged for 2026)¹⁵ — is the most direct threat to consolidated profitability. Watch this number above all others.

2. U.S. treatment volume growth (%). The clearest read on whether the demographic pipeline is intact or eroding. DaVita's normalized volume actually declined modestly in 2025, pressured by elevated patient mortality, a severe flu season, and supply disruptions; management has staked its credibility on a "path back to at least 2% volume growth" that it does not expect to fully materialize until around 2029.¹⁵ This is the metric where the GLP-1 debate will ultimately be settled in the data — and where a multi-year management promise now sits waiting to be tested.

3. Weighted-average share count. The pace at which free cash flow is converted into a shrinking denominator. It is the engine of per-share compounding, and — read alongside leverage — the clearest window into whether capital allocation remains disciplined or is being pushed too hard against a levered balance sheet.

The Bull vs. Bear Debate

The bull case holds that the market catastrophically overreacted to GLP-1s; that "survival expansion" plus structural obesity and diabetes tailwinds keep the patient pipeline intact or even growing over time; that home dialysis and IKC expand margins and deepen payer lock-in; that the duopoly's pricing and cost advantages are durable; and that a relentless buyback machine, backstopped by Berkshire's contractual 45% ownership, continues to compound EPS while providing a valuation anchor. In this view, DaVita is a mispriced utility whose worst fears are narratives, not numbers.

The bear case holds that GLP-1s — and eventually gene therapies and other interventions — will bend the ESRD curve down earlier and harder than the survival-expansion thesis admits, impairing the terminal value of a fixed clinic network; that Marietta hands commercial payers the tools to dismantle the cross-subsidy that is the company's entire profit engine; that persistent clinical-labor inflation permanently compresses margins in a business that cannot raise its government prices; and that an aggressive, debt-funded buyback program has levered the equity to precisely these downside scenarios. In this view, the compounding machine is running on borrowed time and borrowed money.

The activist-style stress test cuts across both. A skeptical investor would press on three things: the capital-allocation record, where the $4.4 billion HealthCare Partners round-trip is a permanent black mark against management's judgment on deploying cash outside the core; the leverage, where buying back a third of the equity has left a balance sheet with limited slack should operating results deteriorate into a legal or clinical shock; and the governance and compliance history, where a pattern of nine-figure fraud settlements and a criminal antitrust trial — however it ended — speaks to a culture that has repeatedly tested legal limits. None of these is disqualifying; all of them are reasons to demand a margin of safety and to watch behavior, not rhetoric.

Current Risk Radar

The material, business-specific risks are narrow and worth naming precisely. Labor and nurse staffing costs remain the dominant controllable pressure, with wage inflation flowing straight to the bottom line in a price-capped model. Reimbursement pressure is structural: annual CMS ESRD payment updates have a long history of failing to keep pace with real-world cost inflation, and the phosphate-binder bundling in 2025 showed how policy changes can raise costs and revenue simultaneously in ways that muddy the margin picture.⁸ Marietta-style employer carve-outs are the tail risk with the largest potential magnitude, because they strike the profit engine directly. To these the modern era has added a cybersecurity dimension — DaVita absorbed roughly $25 million in charges in 2025 tied to a security incident that also disrupted operations³ — a reminder that a business running sensitive patient data across thousands of connected clinics now carries operational-technology risk alongside its clinical and regulatory exposures.

↑ Back to Top

XII. Epilogue & Outro

DaVita is, in the end, the ultimate clinical utility — and one of the strangest compounders in the American market. It was conceived not in a garage but in a single clause of a 1972 spending bill, born of a nation's discomfort with letting committees decide who lives. It was rescued from bankruptcy by a former consultant in a Musketeer costume who turned a dying roll-up into a disciplined machine, and then optimized into a per-share compounding engine admired by the most patient capital in the world. Its profitability rests on an economic sleight of hand — a thin sliver of commercially insured patients quietly subsidizing everyone else — that is at once brilliant and brittle.

Today, under a quieter operator who has traded the sword for a spreadsheet, the company stands at a genuine inflection point. The twin tides of pharmaceutical innovation and judicial disruption are both real and both unresolved, and the honest answer to how they play out is that nobody yet knows. What is certain is that DaVita's story is a case study in the sheer, uncomfortable power of a healthcare duopoly built atop a government entitlement — a business that has spent fifty years proving that the least glamorous corners of the economy can be the most durable, right up until the rules that made them durable begin to change.